Webinar: Understanding Watch and Wait – October 27

If you have a slow-growing or indolent lymphoma or CLL, you may not need treatment. Instead, your doctor may choose a watch and wait approach, also known as active monitoring.

Hear from Dr Annmarie Bosco, Staff Specialist Haematologist at the Prince of Wales Hospital, as she helps us to understand why active monitoring may be offered, what to expect, and how you and your medical team will know if it’s ever time to start treatment.  

Event Details

Date: Tuesday 27th of October
Time: 11:00am to 12:00pm (NSW/VIC/ACT/TAS)
10:00am to 11:00am (QLD)
10:30am to 11:30am (SA/NT)
8:00am to 9:00am (WA)
Location: Online via Zoom – Link sent on registration
Cost: Free – Registration Required

Guest Presenter – Dr Annmarie Bosco

Dr Annmarie Bosco is a haematologist at the Prince of Wales Hospital in Sydney. She has an interest in malignant haematology, especially in myeloma, amyloidosis and lymphoma. Dr Bosco is the Director of the Haematology Clinical Trials Unit at POWH, with trials for new immunotherapies in lymphoma.

If you would like to submit any questions prior to the webinar, please email them through to nurse@lymphoma.org.au or call our Nurse Support Line on 1800 953 081

 

There is limited availability for this event, so secure your spot quickly.
This event has already taken place.
Details
Date: Tuesday 27th of October 2026
Time: 11:00am AEDT - 12:00pm AEDT

Support and information

Contact Lymphoma Australia Today!

Please note:
Lymphoma Australia staff are only able to reply to emails sent in English language.

Useful Definitions

  • Refractory: This means the lymphoma does not get better with treatment. The treatment didn’t work as hoped.
  • Relapsed: This means the lymphoma came back after being gone for a while after treatment.
  • 2nd line treatment: This is the second treatment you get if the first one didn’t work (refractory) or if the lymphoma comes back (relapse).
  • 3rd line treatment: This is the third treatment you get if the second one didn’t work or the lymphoma comes back again.
  • Approved: Available in Australia and listed by the Therapeutics Goods Administration (TGA).
  • Funded: Costs are covered for Australian citizens. This means if you have a Medicare card, you shouldn’t have to pay for the treatment.[WO7]

You need healthy T-cells to make CAR T-cells. For this reason, CAR T-cell therapy cannot be used if you have a T-cell lymphoma – yet.

For more information on CAR T-cells and T-cell lymphoma click here. 

Special Note: Although your T-cells are removed from your blood for CAR T-cell therapy, most of our T-cells live outside of our blood – in our lymph nodes, thymus, spleen and other organs.